Skye Bioscience SKYE
NASDAQ SKYE
$1.07 -0.03 (-2.29%)
At close: Nov 16, 2026 · 4:00 PM EST

Skye Bioscience (SKYE) Short-Term Debt repayments (2022 - 2026)

Updated

Skye Bioscience's Short-Term Debt repayments came in at -$236,681 for Q4 2023, compared with $371,203 a year earlier.

Analysis

Skye Bioscience (SKYE) Short-Term Debt repayments (2022 - 2026) Analysis & Trends

For FY2022, Skye Bioscience's Short-Term Debt repayments was $616,125.

  • The Q4 2023 figure represents the lowest quarterly Short-Term Debt repayments in data going back to Q1 2022.
  • Business Quant data shows SKYE's Short-Term Debt repayments at $67,961 (Q3 2023), $123,413 (Q2 2023) and $45,307 (Q1 2023) in the three quarters before Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Repayment (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 6.63 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn -
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn -
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn -
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn -
10 Skye Bioscience 5.38 Mn -52.34 Mn - -107,287.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -107,287.00
Jun 30, 2026 -107,288.00
Mar 31, 2026 -71,525.00
Dec 31, 2023 -236,681.00
Sep 30, 2023 67,961.00
Jun 30, 2023 123,413.00
Mar 31, 2023 45,307.00
Dec 31, 2022 371,203.00
Sep 30, 2022 91,846.00
Jun 30, 2022 91,846.00
Mar 31, 2022 61,230.00
API Access

Skye Bioscience Short-Term Debt repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-repayments&ticker=SKYE&period=max&api_key=YOUR_API_KEY